TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 8,625 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $156.08 on Wednesday. The firm has a 50 day moving average of $154.40 and a 200-day moving average of $127.98. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $177.37. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The stock has a market capitalization of $5.21 billion, a PE ratio of -459.06 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company’s revenue was up 117.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.03) earnings per share. On average, equities research analysts predict that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Morgan Stanley lifted their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Cantor Fitzgerald began coverage on shares of TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target on the stock. Piper Sandler lifted their price objective on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Finally, Stephens increased their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $171.44.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently modified their holdings of TMDX. Sanctuary Advisors LLC acquired a new position in TransMedics Group during the second quarter worth about $372,000. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of TransMedics Group in the 2nd quarter valued at approximately $420,000. NewEdge Advisors LLC grew its holdings in shares of TransMedics Group by 26.0% during the 2nd quarter. NewEdge Advisors LLC now owns 10,372 shares of the company’s stock valued at $1,562,000 after purchasing an additional 2,140 shares during the last quarter. Creative Planning increased its position in TransMedics Group by 78.3% during the 2nd quarter. Creative Planning now owns 9,173 shares of the company’s stock worth $1,382,000 after purchasing an additional 4,027 shares in the last quarter. Finally, Algert Global LLC bought a new position in TransMedics Group in the 2nd quarter valued at approximately $2,685,000. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.